Background Carbapenem-sparing antibiotics are needed urgently for patients with
complicated intra-abdominal infections (cIAIs). Although several novel antibiotics–novel β …

Background Complicated intra-abdominal infections (cIAIs) result in significant morbidity,
mortality, and cost. Carbapenem-resistant sepsis has increased dramatically in the last …

Background Complicated intra-abdominal infections (cIAIs) remain a leading cause of death
in surgical wards, in which antibiotic treatment is crucial. We aimed to compare the efficacy …

Background Which antimicrobial agents provide the optimal efficacy, safety, and tolerability
for the empirical treatment of complicated intra-abdominal infection (cIAI) remains unclear …

Complicated intra-abdominal infections (cIAIs) are a common cause of morbidity and
mortality in surgical patients. Optimal management of cIAI requires early source control in …

Background The treatment of complicated intra-abdominal infections remains a challenge.
Both optimal medical and surgical therapy (ie, source control) are needed to achieve low …

Complicated intra-abdominal infections (cIAIs) are an important cause of morbidity and
mortality worldwide. They are diagnosed when the initial abdominal organ infection has …

Background: Complicated intra-abdominal infections (cIAIs) are common in clinical practice,
caused by a mixture of aerobic and anaerobic bacteria, increase the risk of mortality …

The purpose of this review is to evaluate the efficacy and safety of ceftazidime/avibactam
and ceftolozane/tazobactam in patients with complicated intra-abdominal infections (cIAI) …

This study reports an integrated analysis of three randomized controlled trials to compare
the clinical efficacies and safety of the ceftazidime–avibactam (CAZ–AVI) combination and …